Doxepin inhibits CYP2D6 activity in vivo

Polish Journal of Pharmacology

Volumn 56, Issue 4, 2004, Pages 491-494

  Szewczuk Bogusławska, Monika ^a   Kiejna, Andrzej ^a   Beszłej, Jan A ^a   Orzechowska Juzwenko, Krystyna ^a   Milejski, Piotr ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

CYP2D6; Doxepin; Inhibition; Tricyclic antidepressants

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; DOXEPIN; SPARTEINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REGIMEN; ENZYME INHIBITION; FEMALE; GAS CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; MALE; METABOLIC RATE; PHENOTYPE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; URINALYSIS;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYTOCHROME P-450 CYP2D6; DEPRESSION; DOXEPIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE;

EID: 9744253798     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Bertilsson L, Dahl M-L, Tybring G: Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl, 1997, 391, 14-21.
2. Daniel WA, Haduch A, Wójcikowski J: Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants. J Pharm Pharmacol 2002, 54, 1545-1552.
3. Danish University Antidepressant Group [DUAG: Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Clin Pharmacol Ther, 1999, 66, 152-165.
4. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ: Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol, 1979, 16, 183-187.
5. Haritos VS, Ghabrial H, Ahokas JT, Ching M: Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics, 2000, 10, 591-603.
6. Hartter S, Tybring G, Friedberg T, Welmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res, 2002, 19, 1035-1038.
7. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation. of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002, 12, 571-580.
8. Labbe L, Sirois C, Pilote S, Arseneault M, Robitaille N, Turgeon J, Hamelin B: Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratio of marker substrates. Pharmacogenetics, 2000, 10, 425-438.
9. Lin JH, Lu AY: Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet, 1998, 35, 361-390.
10. Preskorn SH: Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet, 1997, 32, Suppl 1:1-21.
11. Shin JG, Park JY, Kim MJ, Shon JH, Yoon YR, Cha IJ, Lee SS et al.: Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos, 2002, 30, 1102-1107.
12. Steimer W, Potter JM: Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta, 2002, 315, 137-155.